Evogene (NASDAQ:EVGN) Coverage Initiated at StockNews.com

Equities research analysts at StockNews.com started coverage on shares of Evogene (NASDAQ:EVGN) in a research note issued to investors on Monday. The firm set a “sell” rating on the biotechnology company’s stock.

Evogene Stock Performance

EVGN stock opened at $1.41 on Monday. Evogene has a 1 year low of $1.20 and a 1 year high of $9.00. The company has a fifty day simple moving average of $1.56 and a 200 day simple moving average of $2.00. The firm has a market cap of $7.54 million, a PE ratio of -0.31 and a beta of 1.28.

Evogene (NASDAQ:EVGN) last released its earnings results on Thursday, March 6th. The biotechnology company reported $0.06 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.72) by $0.78. The firm had revenue of $1.61 million during the quarter, compared to analyst estimates of $3.63 million. Evogene had a negative net margin of 314.43% and a negative return on equity of 109.05%. During the same quarter in the previous year, the business earned ($1.30) EPS.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Evogene stock. Citadel Advisors LLC bought a new position in shares of Evogene Ltd. (NASDAQ:EVGN) in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund bought 15,891 shares of the biotechnology company’s stock, valued at approximately $30,000. Citadel Advisors LLC owned about 0.30% of Evogene at the end of the most recent reporting period. 10.40% of the stock is owned by hedge funds and other institutional investors.

About Evogene

Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The company operates through three segments: Agriculture, Human Health, and Industrial Applications.